The FDA said that Novo Nordisk is using illegal monopoly tactics to keep prices of medications sky-high

The System Novo Nordisk Turned Into a Weapon

There is a federal drug registry called the Orange Book. It was designed to help generic drugmakers know which patents they need to clear before bringing a cheaper version of a drug to market. The idea was to make competition possible — to create a clear path for generics to exist.

Novo Nordisk turned that path into a minefield. Under federal law, listing a patent in the Orange Book automatically triggers a 30-month government-enforced freeze on FDA approval of any competing generic application. That means the moment a generic drugmaker files an application, the clock stops — and Novo Nordisk gets roughly two and a half years of government-protected market dominance, no questions asked.

The FTC’s letter, dated April 30, 2024, identifies specific patents the agency believes Novo Nordisk had no legal right to list there in the first place — patents covering drug delivery devices, not the drugs themselves. The FTC describes this as a method of buying time: time in which no cheaper alternative can enter the market, time in which patients pay full price, time in which Novo Nordisk collects.

How Many Patents Are We Talking About?

The volume of disputed patents is not an accident. It is a strategy. The FTC flagged 17 delivery-device patents filed under Ozempic, 16 under Saxenda, and 2 under Victoza. These are not patents on the active drug compound. They cover the pen injector used to administer the drug — a piece of plastic and metal that gets replaced every time someone refills their prescription.

The FTC’s letter is careful to note that the list of disputed patents “should not be read as an exhaustive list of every patent that your company may have improperly submitted.” In other words, this could be the floor, not the ceiling.

The 30-Month Freeze: How a Legal Technicality Becomes a Price Gouge

Here is how the mechanism works in practice. When a generic drugmaker files an application with the FDA, federal law requires them to certify that they are not infringing on any active patents listed in the Orange Book. If the brand-name company challenges that certification, an automatic 30-month stay kicks in — the FDA cannot approve the generic while the legal fight plays out.

Thirty months is two and a half years. Two and a half years of no competition. Two and a half years of patients paying full price for Ozempic, Saxenda, or Victoza. Two and a half years of Novo Nordisk’s revenue flowing unchallenged, with the full structural backing of the federal government’s patent dispute process acting as a shield.

The FTC’s letter points out that beyond the stay itself, the cost of litigating these patent disputes “may disincentivize investments in developing generic drugs.” In plain language: even if a generic company wins the legal fight eventually, the fight is so expensive and time-consuming that many companies will decide before they start that it is not worth trying. Novo Nordisk does not have to win in court. It just has to make the journey painful enough that fewer people attempt it.

The Supreme Court Already Ruled on This — About Novo Nordisk

The FTC’s letter cites a Supreme Court case, Caraco Pharmaceutical Labs v. Novo Nordisk, decided in 2012. In that ruling, the Supreme Court recognized that improper Orange Book listings “prevent or delay generic drug entry.” The defendant in that case was not a generic pharmaceutical company. The defendant was Novo Nordisk. The company has been doing this for over a decade, and a federal regulatory agency is still sending them warning letters in 2024.

The Non-Financial Ledger: What This Actually Costs People

No line in the FTC’s letter says “patient died.” No line says “family went bankrupt.” Government regulatory letters do not write that way. But the entire architecture of what the FTC describes — devices listed where they should not be, patents stacked on top of patents, delays engineered into a system meant to protect competition — only exists for one purpose: to make sure that the price of these drugs stays high, for as long as possible, for as many people as possible.

Ozempic, Saxenda, and Victoza are not luxury goods. They treat Type 2 diabetes and obesity — conditions that, without management, lead to organ failure, amputations, blindness, and heart attacks. The people who need these drugs are disproportionately lower-income, disproportionately uninsured or underinsured, disproportionately the same people who cannot absorb the cost of a brand-name drug when a generic equivalent could exist but for the 35 patents Novo Nordisk planted in the way.

When the FTC writes that “even brief delays in generic competition can reduce patient access to more affordable alternatives,” it is describing a specific type of harm: the harm of a person standing at a pharmacy counter and being told the number, and then doing math they should never have to do. Do I fill this, or do I eat this week. Do I skip a dose to make the bottle last longer. Do I go without until next paycheck. That math happens millions of times, in millions of households, every year — and every year Novo Nordisk keeps a generic off the market is another year that math gets harder.

The patent scheme the FTC describes is not a rounding error in a compliance review. It is a documented, systematic pattern of filing device-related patents — covering pen injectors, not drug compounds — into a federal registry specifically to trigger legal delays that the company knew it could use as a wall against competition. The FTC notes that this practice has been a concern for decades, and Novo Nordisk has already been to the Supreme Court over it. The company absorbed that ruling, kept the strategy in place with different patents, and continued collecting. The human cost of that decision is not abstract — it is the gap between what a generic would cost and what the brand-name costs, multiplied by every patient, every refill, every year the wall held.

Legal Receipts: The Government’s Own Words

These are verbatim passages from the FTC’s April 30, 2024 letter to Novo Nordisk. Nothing paraphrased. Nothing invented.

“Patents improperly listed in the Orange Book may delay lower-cost generic drug competition. By listing their patents in the Orange Book, brand drug companies may benefit from an automatic, 30-month stay of FDA approval of competing generic drug applications.” — FTC Letter to Novo Nordisk, April 30, 2024

“The FTC will continue to use all its tools to halt unlawful business practices that contribute to high drug prices.” — FTC Policy Statement, cited in FTC Letter to Novo Nordisk

“The Orange Book listings identified as improper in this chart should not be read as an exhaustive list of every patent that your company may have improperly submitted. Indeed, your firm bears the burden of listing patents in the Orange Book accurately and in accordance with all relevant statutory and regulatory requirements.” — FTC Letter to Novo Nordisk, April 30, 2024 (emphasis added)

“The FTC intends to scrutinize [such] improper listings as unfair methods of competition in violation of Section 5 of the Federal Trade Commission Act.” — FTC Policy Statement on Orange Book Listings, September 14, 2023, cited in FTC Letter to Novo Nordisk

“We retain the right to take any further action the public interest may require, which may include investigating this conduct as an unfair method of competition under Section 5 of the FTC Act, 15 U.S.C. § 45.” — FTC Letter to Novo Nordisk, April 30, 2024

Societal Impact Mapping

Public Health: The Price Wall Is a Health Crisis

The FTC’s letter is explicit: “even brief delays in generic competition can reduce patient access to more affordable alternatives and increase costs across the entire health care system.” Ozempic and Saxenda address conditions — Type 2 diabetes and obesity — that the CDC classifies as epidemic-level public health crises in the United States. Generics for these drugs would lower the cost of treatment for tens of millions of people. Every month the Orange Book listing scheme holds up a generic application is a month those lower costs do not exist.

Novo Nordisk’s Orange Book filings for Ozempic alone listed 17 device-delivery patents. Each one is a legal instrument that generic makers must confront before they can get FDA approval. The cumulative effect is not theoretical. The FTC references the Supreme Court’s own 2012 acknowledgment that improper listings “prevent or delay generic drug entry” — and that case involved the same company, more than a decade earlier. The public health consequences of an unchecked practice extend forward in time from every year the practice continues.

Economic Inequality: Who Actually Pays This Price

Generic drugs typically cost 80 to 90 percent less than their brand-name equivalents. That gap is not an abstraction. It is the difference between a medication being affordable and being rationed. The people most affected by brand-name-only markets for diabetes and obesity drugs are the same demographic groups most likely to have inadequate insurance coverage, least likely to have the financial cushion to absorb high out-of-pocket costs, and most likely to skip doses when costs spike.

The FTC’s letter makes the distributional argument in systemic terms: improper patent listings “increase costs across the entire health care system.” That burden lands heaviest on individuals and families paying out of pocket or through high-deductible plans. Every year of delayed generic entry translates directly into a transfer of wealth from patients to a company with a market capitalization well into the hundreds of billions of dollars. The Orange Book scheme is not just a regulatory violation. It is a mechanism for extracting money from sick people.

The FTC also notes that litigation costs associated with challenging improperly listed patents may discourage generic companies from even attempting to compete. That chilling effect compounds inequality: it ensures that the market failure compounds itself, with fewer generic challengers over time meaning longer periods of unchecked brand-name pricing for the drugs that millions of the most vulnerable people in the country depend on.

The Cost of a Life Metric